CN107249586A - 用于治疗精神分裂症的伊潘立酮 - Google Patents

用于治疗精神分裂症的伊潘立酮 Download PDF

Info

Publication number
CN107249586A
CN107249586A CN201680010479.4A CN201680010479A CN107249586A CN 107249586 A CN107249586 A CN 107249586A CN 201680010479 A CN201680010479 A CN 201680010479A CN 107249586 A CN107249586 A CN 107249586A
Authority
CN
China
Prior art keywords
iloperidone
daily dose
schizophrenia
individual
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680010479.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·波利梅洛伯罗斯
C·D·沃尔夫冈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Priority to CN202310398029.9A priority Critical patent/CN116211857A/zh
Publication of CN107249586A publication Critical patent/CN107249586A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680010479.4A 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮 Pending CN107249586A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310398029.9A CN116211857A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US62/117,173 2015-02-17
US201562172436P 2015-06-08 2015-06-08
US62/172,436 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310398029.9A Division CN116211857A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Publications (1)

Publication Number Publication Date
CN107249586A true CN107249586A (zh) 2017-10-13

Family

ID=55532275

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680010479.4A Pending CN107249586A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮
CN202310398029.9A Pending CN116211857A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310398029.9A Pending CN116211857A (zh) 2015-02-17 2016-02-17 用于治疗精神分裂症的伊潘立酮

Country Status (9)

Country Link
US (2) US10441580B2 (https=)
EP (1) EP3258935B1 (https=)
JP (1) JP6885649B2 (https=)
KR (1) KR102870956B1 (https=)
CN (2) CN107249586A (https=)
BR (1) BR112017017608A2 (https=)
CA (1) CA2976383C (https=)
ES (1) ES2870498T3 (https=)
WO (1) WO2016134049A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
AU2023408198A1 (en) * 2022-12-19 2025-05-29 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
IL324466A (en) 2023-06-02 2026-01-01 Vanda Pharmaceuticals Inc Method of treatment with iloperidone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039663A2 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
WO2009036056A1 (en) * 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
WO2010132866A1 (en) * 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504783A (ja) 2001-08-31 2005-02-17 ノバルティス アクチエンゲゼルシャフト イロペリドン代謝産物の光学異性体
BRPI0213564B8 (pt) 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
JP2015502941A (ja) * 2011-12-02 2015-01-29 大日本住友製薬株式会社 少なくとも１つのｃｎｓ障害の治療、予防、および／または管理のためのルラシドン新規投与レジメンおよびその使用
CA2865845C (en) 2012-03-14 2020-02-18 Vanda Pharmaceuticals Inc. An iloperidone metabolite for use in the treatment of psychiatric disorders
CA2882708A1 (en) * 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039663A2 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
WO2009036056A1 (en) * 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
WO2010132866A1 (en) * 2009-05-15 2010-11-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRIAN L CRABTREE ET AL.: "Iloperidone for the management of adults with schizophrenia", 《CLINICAL THERAPEUTICS》 *
HALE,K.S.: "Iloperidone-a second-generation antipsychotic for the treatment of acute schizophrenia", 《JOURNAL OF PHARMACY TECHNOLOGY》 *
SCOTT ET AL.: "Iloperidone:In Schizophrenia", 《CNS DRUGS》 *
VIO CACCIA ET AL.: "New atypical antipsychotics for schizophrenia:iloperidone", 《DRUG DESIGN,DEVELOPMENT AND THERAPY》 *
WEIDEN PETER J ET AL.: "Safety Profile of Iloperidone:A Pooled Analysis of 6-Week Acute-Phase Pivotal Trials", 《JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY》 *
包再梅等: "《内科学》", 28 February 2014, 华中科技大学出版社 *
卫生部合理用药专家委员会: "《中国医师药师临床用药指南（第2版）》", 31 July 2014, 重庆出版集团重庆出版社 *

Also Published As

Publication number Publication date
CA2976383C (en) 2023-05-23
US10441580B2 (en) 2019-10-15
HK1248551A1 (zh) 2018-10-19
JP2018505901A (ja) 2018-03-01
US20190388412A1 (en) 2019-12-26
WO2016134049A1 (en) 2016-08-25
BR112017017608A2 (en) 2018-05-08
CN116211857A (zh) 2023-06-06
US10987346B2 (en) 2021-04-27
US20180021324A1 (en) 2018-01-25
KR102870956B1 (ko) 2025-10-16
EP3258935B1 (en) 2021-04-07
CA2976383A1 (en) 2016-08-25
KR20170118830A (ko) 2017-10-25
JP6885649B2 (ja) 2021-06-16
ES2870498T3 (es) 2021-10-27
EP3258935A1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
Bowden et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Latorre et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICS
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US10987346B2 (en) Iloperidone for the treatment of schizophrenia
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
Marquez et al. Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin
JP2019023195A (ja) Ｌ−４−クロロキヌレニンの剤形及び治療的使用
TWI888340B (zh) 用於預防或治療貓之全身性疾病之血管收縮素ii受體拮抗劑
Lickliter et al. Safety and pharmacokinetics (PK) in humans of intravenous ETX2514, a β-lactamase inhibitor (BLI) which broadly inhibits Amber class A, C, and D β-lactamases
Prantera et al. Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial
JP6420923B1 (ja) 医薬
HK1248551B (en) Iloperidone for the treatment of schizophrenia
Qiu et al. Metformin alleviates ribociclib-induced lung injury by restoring impaired autophagy via targeting Mucolipin-1
Al Mamun et al. P258 Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD
Singh et al. P256 Aclidinium bromide: a Phase IIb, dose-finding study
WO2023149539A1 (ja) 筋萎縮性側索硬化症の治療又は進展抑制のための薬剤
JP2023182667A (ja) エルトロンボパグの投与計画
Xin et al. Zhengzhou University, Zhengzhou, China
CN102149389A (zh) 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途
Short et al. P257 Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD
Møller et al. Complications of anaesthesia
Detke et al. P. 3. a. 015 Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
CN108938645A (zh) 一种抗精神病药物组合物
JP2016515616A (ja) エスリカルバゼピン又はエスリカルバゼピン酢酸塩を伴う処置

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20171013

RJ01 Rejection of invention patent application after publication